Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Triggered ferroptotic polymer micelles for reversing multidrug resistance to chemotherapy.

Gao M, Deng J, Liu F, Fan A, Wang Y, Wu H, Ding D, Kong D, Wang Z, Peer D, Zhao Y.

Biomaterials. 2019 Sep 7;223:119486. doi: 10.1016/j.biomaterials.2019.119486. [Epub ahead of print]

PMID:
31520887
2.

Reprogramming the lymphocyte axis for advanced immunotherapy.

Moghimi SM, Peer D.

Adv Drug Deliv Rev. 2019 Feb 15;141:1-2. doi: 10.1016/j.addr.2019.07.001. No abstract available.

PMID:
31375166
3.

Publisher Correction: On the issue of transparency and reproducibility in nanomedicine.

Leong HS, Butler KS, Brinker CJ, Azzawi M, Conlan S, Dufès C, Owen A, Rannard S, Scott C, Chen C, Dobrovolskaia MA, Kozlov SV, Prina-Mello A, Schmid R, Wick P, Caputo F, Boisseau P, Crist RM, McNeil SE, Fadeel B, Tran L, Hansen SF, Hartmann NB, Clausen LPW, Skjolding LM, Baun A, Ågerstrand M, Gu Z, Lamprou DA, Hoskins C, Huang L, Song W, Cao H, Liu X, Jandt KD, Jiang W, Kim BYS, Wheeler KE, Chetwynd AJ, Lynch I, Moghimi SM, Nel A, Xia T, Weiss PS, Sarmento B, das Neves J, Santos HA, Santos L, Mitragotri S, Little S, Peer D, Amiji MM, Alonso MJ, Petri-Fink A, Balog S, Lee A, Drasler B, Rothen-Rutishauser B, Wilhelm S, Acar H, Harrison RG, Mao C, Mukherjee P, Ramesh R, McNally LR, Busatto S, Wolfram J, Bergese P, Ferrari M, Fang RH, Zhang L, Zheng J, Peng C, Du B, Yu M, Charron DM, Zheng G, Pastore C.

Nat Nanotechnol. 2019 Sep;14(9):902. doi: 10.1038/s41565-019-0538-3.

PMID:
31358944
4.

Publisher Correction: On the issue of transparency and reproducibility in nanomedicine.

Leong HS, Butler KS, Brinker CJ, Azzawi M, Conlan S, Dufès C, Owen A, Rannard S, Scott C, Chen C, Dobrovolskaia MA, Kozlov SV, Prina-Mello A, Schmid R, Wick P, Caputo F, Boisseau P, Crist RM, McNeil SE, Fadeel B, Tran L, Hansen SF, Hartmann NB, Clausen LPW, Skjolding LM, Baun A, Ågerstrand M, Gu Z, Lamprou DA, Hoskins C, Huang L, Song W, Cao H, Liu X, Jandt KD, Jiang W, Kim BYS, Wheeler KE, Chetwynd AJ, Lynch I, Moghimi SM, Nel A, Xia T, Weiss PS, Sarmento B, Neves JD, Santos HA, Santos L, Mitragotri S, Little S, Peer D, Amiji MM, Alonso MJ, Petri-Fink A, Balog S, Lee A, Drasler B, Rothen-Rutishauser B, Wilhelm S, Acar H, Harrison RG, Mao C, Mukherjee P, Ramesh R, McNally LR, Busatto S, Wolfram J, Bergese P, Ferrari M, Fang RH, Zhang L, Zheng J, Peng C, Du B, Yu M, Charron DM, Zheng G, Pastore C.

Nat Nanotechnol. 2019 Aug;14(8):811. doi: 10.1038/s41565-019-0523-x.

PMID:
31289407
5.

On the issue of transparency and reproducibility in nanomedicine.

Leong HS, Butler KS, Brinker CJ, Azzawi M, Conlan S, Dufés C, Owen A, Rannard S, Scott C, Chen C, Dobrovolskaia MA, Kozlov SV, Prina-Mello A, Schmid R, Wick P, Caputo F, Boisseau P, Crist RM, McNeil SE, Fadeel B, Tran L, Hansen SF, Hartmann NB, Clausen LPW, Skjolding LM, Baun A, Ågerstrand M, Gu Z, Lamprou DA, Hoskins C, Huang L, Song W, Cao H, Liu X, Jandt KD, Jiang W, Kim BYS, Wheeler KE, Chetwynd AJ, Lynch I, Moghimi SM, Nel A, Xia T, Weiss PS, Sarmento B, das Neves J, Santos HA, Santos L, Mitragotri S, Little S, Peer D, Amiji MM, Alonso MJ, Petri-Fink A, Balog S, Lee A, Drasler B, Rothen-Rutishauser B, Wilhelm S, Acar H, Harrison RG, Mao C, Mukherjee P, Ramesh R, McNally LR, Busatto S, Wolfram J, Bergese P, Ferrari M, Fang RH, Zhang L, Zheng J, Peng C, Du B, Yu M, Charron DM, Zheng G, Pastore C.

Nat Nanotechnol. 2019 Jul;14(7):629-635. doi: 10.1038/s41565-019-0496-9. No abstract available. Erratum in: Nat Nanotechnol. 2019 Aug;14(8):811. Nat Nanotechnol. 2019 Sep;14(9):902.

PMID:
31270452
6.

Therapeutic mRNA delivery to leukocytes.

Granot-Matok Y, Kon E, Dammes N, Mechtinger G, Peer D.

J Control Release. 2019 Jul 10;305:165-175. doi: 10.1016/j.jconrel.2019.05.032. Epub 2019 May 21. Review.

PMID:
31121277
7.

Systemic Modulation of Lymphocyte Subsets Using siRNAs Delivered via Targeted Lipid Nanoparticles.

Hazan-Halevy I, Rosenblum D, Ramishetti S, Peer D.

Methods Mol Biol. 2019;1974:151-159. doi: 10.1007/978-1-4939-9220-1_11.

PMID:
31099001
8.

Challenges in IBD Research: Novel Technologies.

Dhyani M, Joshi N, Bemelman WA, Gee MS, Yajnik V, D'Hoore A, Traverso G, Donowitz M, Mostoslavsky G, Lu TK, Lineberry N, Niessen HG, Peer D, Braun J, Delaney CP, Dubinsky MC, Guillory AN, Pereira M, Shtraizent N, Honig G, Polk DB, Hurtado-Lorenzo A, Karp JM, Michelassi F.

Inflamm Bowel Dis. 2019 May 16;25(Supplement_2):S24-S30. doi: 10.1093/ibd/izz077.

PMID:
31095703
9.

A tissue chamber chip for assessing nanoparticle mobility in the extravascular space.

Lusi V, Moore TL, Laurino F, Coclite A, Perreira R, Ferreira M, Rizzuti I, Palomba R, Zunino P, Duocastella M, Mizrahy S, Peer D, Decuzzi P.

Biomed Microdevices. 2019 Apr 6;21(2):41. doi: 10.1007/s10544-019-0398-5.

PMID:
30955101
10.

Engineering lymphocytes with RNAi.

Ramishetti S, Peer D.

Adv Drug Deliv Rev. 2019 Feb 15;141:55-66. doi: 10.1016/j.addr.2018.12.002. Epub 2018 Dec 6. Review.

PMID:
30529305
11.

Gene Silencing in the Right Place at the Right Time.

Gutkin A, Peer D.

Mol Ther. 2018 Dec 5;26(12):2875. doi: 10.1016/j.ymthe.2018.11.008. Epub 2018 Nov 16. No abstract available.

12.

Personalized Hydrogels for Engineering Diverse Fully Autologous Tissue Implants.

Edri R, Gal I, Noor N, Harel T, Fleischer S, Adadi N, Green O, Shabat D, Heller L, Shapira A, Gat-Viks I, Peer D, Dvir T.

Adv Mater. 2019 Jan;31(1):e1803895. doi: 10.1002/adma.201803895. Epub 2018 Nov 8.

PMID:
30406960
13.

Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes.

Veiga N, Goldsmith M, Granot Y, Rosenblum D, Dammes N, Kedmi R, Ramishetti S, Peer D.

Nat Commun. 2018 Oct 29;9(1):4493. doi: 10.1038/s41467-018-06936-1.

14.

Gene Silencing in the Right Place at the Right Time.

Gutkin A, Peer D.

Mol Ther. 2018 Nov 7;26(11):2539-2541. doi: 10.1016/j.ymthe.2018.10.005. Epub 2018 Oct 23. No abstract available. Erratum in: Mol Ther. 2018 Dec 5;26(12):2875.

PMID:
30366821
15.

Targeting central nervous system pathologies with nanomedicines.

Mizrahy S, Gutkin A, Decuzzi P, Peer D.

J Drug Target. 2019 Jun - Jul;27(5-6):542-554. doi: 10.1080/1061186X.2018.1533556. Epub 2018 Oct 18.

PMID:
30296187
16.

Progress and challenges towards targeted delivery of cancer therapeutics.

Rosenblum D, Joshi N, Tao W, Karp JM, Peer D.

Nat Commun. 2018 Apr 12;9(1):1410. doi: 10.1038/s41467-018-03705-y. Review.

17.

A modular platform for targeted RNAi therapeutics.

Kedmi R, Veiga N, Ramishetti S, Goldsmith M, Rosenblum D, Dammes N, Hazan-Halevy I, Nahary L, Leviatan-Ben-Arye S, Harlev M, Behlke M, Benhar I, Lieberman J, Peer D.

Nat Nanotechnol. 2018 Mar;13(3):214-219. doi: 10.1038/s41565-017-0043-5. Epub 2018 Jan 29.

PMID:
29379205
18.

Focus on RNA interference: from nanoformulations to in vivo delivery.

Karp JM, Peer D.

Nanotechnology. 2018 Jan 5;29(1):010201. doi: 10.1088/1361-6528/aa98e3. No abstract available.

PMID:
29185433
19.

Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint.

Granot Y, Peer D.

Semin Immunol. 2017 Dec;34:68-77. doi: 10.1016/j.smim.2017.08.015. Epub 2017 Sep 7. Review.

PMID:
28890238
20.

Next-Generation Lipids in RNA Interference Therapeutics.

Rietwyk S, Peer D.

ACS Nano. 2017 Aug 22;11(8):7572-7586. doi: 10.1021/acsnano.7b04734. Epub 2017 Jul 24.

PMID:
28727419
21.

Emerging Trends in Micro- and Nanoscale Technologies in Medicine: From Basic Discoveries to Translation.

Alvarez MM, Aizenberg J, Analoui M, Andrews AM, Bisker G, Boyden ES, Kamm RD, Karp JM, Mooney DJ, Oklu R, Peer D, Stolzoff M, Strano MS, Trujillo-de Santiago G, Webster TJ, Weiss PS, Khademhosseini A.

ACS Nano. 2017 Jun 27;11(6):5195-5214. doi: 10.1021/acsnano.7b01493. Epub 2017 May 19. Review.

PMID:
28524668
22.

Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes.

Mizrahy S, Hazan-Halevy I, Dammes N, Landesman-Milo D, Peer D.

Mol Ther. 2017 Jul 5;25(7):1491-1500. doi: 10.1016/j.ymthe.2017.03.001. Epub 2017 Apr 6. Review.

23.

Advanced Strategies in Immune Modulation of Cancer Using Lipid-Based Nanoparticles.

Mizrahy S, Hazan-Halevy I, Landesman-Milo D, Ng BD, Peer D.

Front Immunol. 2017 Feb 6;8:69. doi: 10.3389/fimmu.2017.00069. eCollection 2017.

24.

Orchestrating a Symphony on a Single Conjugate: Aptamer Targeting, Gene Silencing, and Immunomodulation to Enhance Antitumor Response.

Ng BD, Peer D.

Mol Ther. 2017 Jan 4;25(1):5-7. doi: 10.1016/j.ymthe.2016.12.003. Epub 2017 Jan 4. No abstract available.

25.

Drug Delivery Research for the Future: Expanding the Nano Horizons and Beyond.

Mitragotri S, Lammers T, Bae YH, Schwendeman S, De Smedt S, Leroux JC, Peer D, Kwon IC, Harashima H, Kikuchi A, Oh YK, Torchilin V, Hennink W, Hanes J, Park K.

J Control Release. 2017 Jan 28;246:183-184. doi: 10.1016/j.jconrel.2017.01.011. No abstract available.

PMID:
28110715
26.

Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions.

Anchordoquy TJ, Barenholz Y, Boraschi D, Chorny M, Decuzzi P, Dobrovolskaia MA, Farhangrazi ZS, Farrell D, Gabizon A, Ghandehari H, Godin B, La-Beck NM, Ljubimova J, Moghimi SM, Pagliaro L, Park JH, Peer D, Ruoslahti E, Serkova NJ, Simberg D.

ACS Nano. 2017 Jan 24;11(1):12-18. doi: 10.1021/acsnano.6b08244. Epub 2017 Jan 9.

27.

Comprehensive and Systematic Analysis of the Immunocompatibility of Polyelectrolyte Capsules.

Zyuzin MV, Díez P, Goldsmith M, Carregal-Romero S, Teodosio C, Rejman J, Feliu N, Escudero A, Almendral MJ, Linne U, Peer D, Fuentes M, Parak WJ.

Bioconjug Chem. 2017 Feb 15;28(2):556-564. doi: 10.1021/acs.bioconjchem.6b00657. Epub 2017 Jan 20.

PMID:
28040889
28.

ECM-based macroporous sponges release essential factors to support the growth of hematopoietic cells.

Soffer-Tsur N, Peer D, Dvir T.

J Control Release. 2017 Jul 10;257:84-90. doi: 10.1016/j.jconrel.2016.09.021. Epub 2016 Sep 23.

PMID:
27671876
29.

Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines.

Hazan-Halevy I, Landesman-Milo D, Rosenblum D, Mizrahy S, Ng BD, Peer D.

J Control Release. 2016 Dec 28;244(Pt B):149-156. doi: 10.1016/j.jconrel.2016.07.052. Epub 2016 Aug 2. Review.

PMID:
27491881
30.

Zooming in on selectins in cancer.

Kedmi R, Peer D.

Sci Transl Med. 2016 Jun 29;8(345):345fs11. doi: 10.1126/scitranslmed.aag1802. Review.

PMID:
27358495
31.

Harnessing nanomedicine for therapeutic intervention in glioblastoma.

Gutkin A, Cohen ZR, Peer D.

Expert Opin Drug Deliv. 2016 Nov;13(11):1573-1582. Epub 2016 Jun 27. Review.

PMID:
27292970
32.

Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles.

Ramishetti S, Landesman-Milo D, Peer D.

J Drug Target. 2016 Nov;24(9):780-786. Epub 2016 May 4. Review.

PMID:
27030014
33.

Colitis ImmunoPET: Defining Target Cell Populations and Optimizing Pharmacokinetics.

Dearling JL, Daka A, Veiga N, Peer D, Packard AB.

Inflamm Bowel Dis. 2016 Mar;22(3):529-38. doi: 10.1097/MIB.0000000000000677.

PMID:
26841223
34.

RNA nanomedicines: the next generation drugs?

Singh MS, Peer D.

Curr Opin Biotechnol. 2016 Jun;39:28-34. doi: 10.1016/j.copbio.2015.12.011. Epub 2016 Jan 11. Review.

PMID:
26773301
35.

siRNA delivery: current trends and future perspectives.

Singh MS, Peer D.

Ther Deliv. 2016;7(2):51-3. doi: 10.4155/tde.15.88. Epub 2016 Jan 15. No abstract available.

36.

Transforming Nanomedicines From Lab Scale Production to Novel Clinical Modality.

Landesman-Milo D, Peer D.

Bioconjug Chem. 2016 Apr 20;27(4):855-62. doi: 10.1021/acs.bioconjchem.5b00607. Epub 2016 Jan 20. Review.

PMID:
26734836
37.

Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.

Weinstein S, Toker IA, Emmanuel R, Ramishetti S, Hazan-Halevy I, Rosenblum D, Goldsmith M, Abraham A, Benjamini O, Bairey O, Raanani P, Nagler A, Lieberman J, Peer D.

Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):E16-22. doi: 10.1073/pnas.1519273113. Epub 2015 Dec 23.

38.

Modulation of Immune Response Using Engineered Nanoparticle Surfaces.

Moyano DF, Liu Y, Peer D, Rotello VM.

Small. 2016 Jan 6;12(1):76-82. doi: 10.1002/smll.201502273. Epub 2015 Nov 30. Review.

39.

Platelet mimicry: The emperor's new clothes?

Moghimi SM, Hunter AC, Peer D.

Nanomedicine. 2016 Jan;12(1):245-8. doi: 10.1016/j.nano.2015.09.005. Epub 2015 Sep 25.

PMID:
26409192
40.

Nanodiamonds of Laser Synthesis for Biomedical Applications.

Perevedentseva E, Peer D, Uvarov V, Zousman B, Levinson O.

J Nanosci Nanotechnol. 2015 Feb;15(2):1045-52.

PMID:
26353611
41.

Dielectrophoretic characterization of cells in a stationary nanoliter droplet array with generated chemical gradients.

Ben-Arye T, Park S, Shemesh J, Peer D, Levenberg S, Yossifon G.

Biomed Microdevices. 2015 Oct;17(5):91. doi: 10.1007/s10544-015-9996-z.

PMID:
26286862
42.

Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles.

Ramishetti S, Kedmi R, Goldsmith M, Leonard F, Sprague AG, Godin B, Gozin M, Cullis PR, Dykxhoorn DM, Peer D.

ACS Nano. 2015 Jul 28;9(7):6706-16. doi: 10.1021/acsnano.5b02796. Epub 2015 Jun 10.

PMID:
26042619
43.

Serum chemokine network correlates with chemotherapy in non-small cell lung cancer.

Yang D, Zhou J, Zeng T, Yang Z, Wang X, Hu J, Song Y, Chen L, Peer D, Wang X, Bai C.

Cancer Lett. 2015 Aug 28;365(1):57-67. doi: 10.1016/j.canlet.2015.05.001. Epub 2015 May 11.

PMID:
25976768
44.

Nanomedicine as an emerging platform for metastatic lung cancer therapy.

Landesman-Milo D, Ramishetti S, Peer D.

Cancer Metastasis Rev. 2015 Jun;34(2):291-301. doi: 10.1007/s10555-015-9554-4. Review.

PMID:
25948376
45.

Cell-specific uptake of mantle cell lymphoma-derived exosomes by malignant and non-malignant B-lymphocytes.

Hazan-Halevy I, Rosenblum D, Weinstein S, Bairey O, Raanani P, Peer D.

Cancer Lett. 2015 Aug 1;364(1):59-69. doi: 10.1016/j.canlet.2015.04.026. Epub 2015 Apr 28.

46.

The human P-glycoprotein transporter enhances the type I interferon response to Listeria monocytogenes infection.

Sigal N, Kaplan Zeevi M, Weinstein S, Peer D, Herskovits AA.

Infect Immun. 2015 Jun;83(6):2358-68. doi: 10.1128/IAI.00380-15. Epub 2015 Mar 30.

47.

Metastability in lipid based particles exhibits temporally deterministic and controllable behavior.

Jacoby G, Cohen K, Barkan K, Talmon Y, Peer D, Beck R.

Sci Rep. 2015 Mar 30;5:9481. doi: 10.1038/srep09481.

48.

Toxicity profiling of several common RNAi-based nanomedicines: a comparative study.

Landesman-Milo D, Peer D.

Drug Deliv Transl Res. 2014 Feb;4(1):96-103. doi: 10.1007/s13346-013-0158-7.

PMID:
25786620
49.

RNA interference-based therapeutics and diagnostics.

Peer D, Howard KA.

Drug Deliv Transl Res. 2014 Feb;4(1):1-2. doi: 10.1007/s13346-013-0182-7. No abstract available.

PMID:
25786612
50.

Triggered-release polymeric conjugate micelles for on-demand intracellular drug delivery.

Cao Y, Gao M, Chen C, Fan A, Zhang J, Kong D, Wang Z, Peer D, Zhao Y.

Nanotechnology. 2015 Mar 20;26(11):115101. doi: 10.1088/0957-4484/26/11/115101. Epub 2015 Feb 24.

PMID:
25708980

Supplemental Content

Support Center